pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,322 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1183Endpoints903BioPharma Dive347BioSpace317Fierce Biotech301onclive165raps106globenewswire health73
therapy area
allOncology7751Rare Disease1885Cardiology1770Immunology1511Hematology1328Vaccines1204Pulmonology
  • Experts discuss strengths and limits of real-world studies for prostate cancer drug comparisons
    Experts highlighted that observational and propensity-matched analyses are increasingly used to compare treatments for metastatic castration-sensitive prostate cancer. They noted that such real-wo…
    onclive · 4mo agoNeutral↗ source
  • Hospital shootings have risen steadily since 2000, according to new data
    A new analysis shows that incidents of gunfire inside U.S. hospitals have been climbing each year since 2000. The report notes a clear upward trend in the frequency of these events, raising concer…
    STAT · 4mo agoNeutral↗ source
← prev
page 120 of 133
next →
fda recalls70
fda medwatch60
fda press38
1200
Psychiatry & CNS870
Ophthalmology502
Pain482
Endocrinology & Metabolism481
Infectious Disease444
Study finds researchers become less disruptive as they age, favoring incremental work
A new study published in Science reports that scientists tend to produce their most disruptive work early in their careers, but shift toward less groundbreaking research as they get older. The ana…
STAT · 4mo agoNeutral↗ source
  • CDC’s cruise ship health chief Luis Rodríguez retires amid hantavirus outbreak on MV Hondius
    The Centers for Disease Control and Prevention announced that Luis Rodríguez, who has been with the Vessel Sanitation Program since 2010 and its chief since 2023, will retire. His departure comes…
    STAT · 4mo agoNeutral↗ source
  • Pennsylvania files lawsuit against Character.AI for presenting chatbot as licensed physician
    The Commonwealth of Pennsylvania has filed a lawsuit against Character.AI, a startup that offers users the ability to converse with AI-generated personas. The suit alleges that the company illegall…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • AAAS elects oncology leaders Guise and Watowich, highlight mentorship for early-career researchers
    Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, have been elected as fellows of the American Association for the Advancement of Science (AAAS). The fellowship recognizes scientists wh…
    onclive · 4mo agoPositive↗ source
  • STAT Health Tech newsletter highlights OpenAI health policy ideas and Dexcom CGM updates
    The latest STAT Health Tech newsletter, edited by Mario Aguilar, offers a roundup of recent technology developments in health care. OpenAI proposes a set of health policy recommendations aimed at…
    STAT · 4mo agoNeutral↗ source
  • Oncology fellows urged to nurture curiosity throughout training
    Megan Dupuis, an early-career oncology faculty member at Vanderbilt University Medical Center, shares a story from a rural clinic visit where a patient’s personal background – a one-room schoolhous…
    onclive · 4mo agoPositive↗ source
  • STAT+: Next-gen Duchenne drug from Entrada disappoints
    A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.
    STAT · 4mo ago↗ source
  • Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
    Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s po…
    Endpoints · 4mo ago↗ source
  • STAT+: Color me skeptical: Drinking gold is not an ALS cure
    In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.
    STAT · 4mo ago↗ source
  • STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
    The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
    STAT · 4mo ago↗ source
  • STAT+: What was lost at the FDA
    What was lost at the FDA: A year after DOGE’s cuts, six agency staffers describe the work they never thought they’d leave.
    STAT · 4mo ago↗ source
  • Opinion: Eugene Braunwald, ‘father of modern cardiology,’ told me he had two dreams. One came true
    Legendary cardiologist Eugene Braunwald had two visions for his career. One of them came true.
    STAT · 4mo ago↗ source
  • Cruise ship hantavirus outbreak worries experts, though they discount pandemic fears
    Scientists are worried that hantaviruses haven’t been as well studied as they ought to be, but not that the MV Hondius cruise ship is ground zero for the next pandemic.
    STAT · 4mo ago↗ source
  • MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT
    R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies like pimicotinib in TGCT enables a tumor biology–informed approach to care.
    onclive · 4mo ago↗ source
  • STAT+: Oregon hospitals won’t outsource to national physician chain after all
    Faced with stiff local opposition and a possible loss in court, PeaceHealth drops plan to replace Eugene Emergency Physicians with staffing chain ApolloMD.
    STAT · 4mo ago↗ source
  • Trump administration’s drug strategy is at odds with recent actions on funding, policy
    The White House nods to medication-assisted treatment and fentanyl test strips, despite recently placing new limits.
    STAT · 4mo ago↗ source
  • Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
    Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
    onclive · 4mo ago↗ source
  • Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
    Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.
    onclive · 4mo ago↗ source
  • Amgen, AbbVie say IRA negotiations impacted Q1 sales
    At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in thei…
    Endpoints · 4mo ago↗ source
  • Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC
    Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC.
    onclive · 4mo ago↗ source
  • Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
    Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.
    onclive · 4mo ago↗ source
  • Lilly plans new $4.5B manufacturing investment in Indiana
    Eli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana as drugmakers pledge more US projects. The world’s largest pharma company, headquarter…
    Endpoints · 4mo ago↗ source
  • BeOne culls five cancer programs and an autoimmune Phase 2
    BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experi…
    Endpoints · 4mo ago↗ source